Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection

Código QR

Understanding the antiviral effects of RNAi-based therapy in HBeAg-positive chronic hepatitis B infection

Abstract The RNA interference (RNAi) drug ARC-520 was shown to be effective in reducing serum hepatitis B virus (HBV) DNA, hepatitis B e antigen (HBeAg) and hepatitis B surface antigen (HBsAg) in HBeAg-positive patients treated with a single dose of ARC-520 and daily nucleosidic analogue (entecavir)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Sarah Kadelka, Harel Dahari, Stanca M. Ciupe
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/31eebecaa82d4111a962dfeba05e6b78
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares

Meta-omics characteristics of intestinal microbiota associated to HBeAg seroconversion induced by oral antiviral therapy
por: Yu-Li Zeng, et al.
Publicado: (2021)

A Missense Variant in Granulysin is Associated with the Efficacy of Pegylated-Interferon-Alpha Therapy in Chinese Patients with HBeAg-Positive Chronic Hepatitis B
por: Li J, et al.
Publicado: (2021)

Electronic Health Informatics Data To Describe Clearance Dynamics of Hepatitis B Surface Antigen (HBsAg) and e Antigen (HBeAg) in Chronic Hepatitis B Virus Infection
por: Louise O. Downs, et al.
Publicado: (2019)

Alteration of the Immune Microenvironment in HBsAg and HBeAg Dual-Positive Pregnant Women Presenting a High HBV Viral Load
por: Gao F, et al.
Publicado: (2021)

Sophisticated viral quasispecies with a genotype-related pattern of mutations in the hepatitis B X gene of HBeAg-ve chronically infected patients
por: Maria Francesca Cortese, et al.
Publicado: (2021)

Changes in the Prevalence of HBsAg and HBeAg: a Study of 8696 Parturients in a Well Vaccinated Area
por: Chen-Hsuan Wu, et al.
Publicado: (2017)

Favorable Response to Long-term Nucleos(t)ide Analogue Therapy in HBeAg-positive Patients with High Serum Fucosyl-Agalactosyl IgG
por: Cheng-Hsun Ho, et al.
Publicado: (2017)

Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis.
por: Hui Liu, et al.
Publicado: (2021)

Amino acid residues at core protein dimer-dimer interface modulate multiple steps of hepatitis B virus replication and HBeAg biogenesis
por: Hui Liu, et al.
Publicado: (2021)

Incidence and predictors of HBV relapse after cessation of nucleoside analogues in HBeAg-negative patients with HBsAg ≤ 200 IU/mL
por: Chih-Chien Yao, et al.
Publicado: (2017)

Tratamiento de infección por virus de hepatitis B con entecavir A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. Chang T, Gish R G, de Man R, Gadano A. N Engl J Med 2006; Vol 354: 1001-10
por: Calvo A,Mario
Publicado: (2006)

Antiviral therapy for chronic hepatitis B in the indeterminate phase is urgent
por: JIANG Jun
Publicado: (2021)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
por: Irina RUSU, et al.
Publicado: (2020)

An Updated View on the Antiviral Therapy of Hepatitis C in Chronic Kidney Disease
por: Fabrizio Fabrizi, et al.
Publicado: (2021)

Prevalence of HBV DNA in anti-HBe+ chronic HBV carriers in Babol, 2002
por: MR Hassanjani Roshan, et al.
Publicado: (2004)

Ultra-long-acting (XLA) antivirals for chronic viral hepatitis
por: Vicente Soriano, et al.
Publicado: (2022)

MONITORING OF LONG-TERM ANTIVIRAL TREATMENT OF CHRONIC HEPATITIS B
por: A. A. Sukhoruk, et al.
Publicado: (2018)

Prediction for HBsAg seroconversion in children with chronic hepatitis B
por: Yan-Wei Zhong, et al.
Publicado: (2021)

How far are we from the “Treat all” era of antiviral therapy for chronic hepatitis B
por: DING Yang
Publicado: (2021)

Sustained Antiviral and Liver Protection by a Nasal Therapeutic Vaccine (NASVAC, Containing Both HBsAg and HBcAg) in Patients with Chronic Hepatitis B: 2-Year Follow-Up of Phase III Clinical Trial
por: Sheikh Mohammad Fazle Akbar, et al.
Publicado: (2021)

Patients with chronic hepatitis B virus infection in the indeterminate phase may benefit from antiviral therapy
por: XU Jinghang
Publicado: (2021)

Patients in the indeterminate phase of chronic hepatitis B virus infection should receive active antiviral therapy
por: WANG Jingyue
Publicado: (2021)

Beyond identity: Understanding the contribution of the 5' nucleotide of the antisense strand to RNAi activity.
por: Peizhen Yang, et al.
Publicado: (2021)

Metabolic syndrome in chronic hepatitis C infection: does it still matter in the era of directly acting antiviral therapy?
por: Lim TR
Publicado: (2014)

A Review on Extrahepatic Manifestations of Chronic Hepatitis C Virus Infection and the Impact of Direct-Acting Antiviral Therapy
por: Cesare Mazzaro, et al.
Publicado: (2021)

RNAi efficacy is enhanced by chronic dsRNA feeding in pollen beetle
por: Jonathan Willow, et al.
Publicado: (2021)

Blockade of immunosuppressive cytokines restores NK cell antiviral function in chronic hepatitis B virus infection.
por: Dimitra Peppa, et al.
Publicado: (2010)

A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection.
por: Bambang S Adiwijaya, et al.
Publicado: (2012)

Frequency of hepatitis B virus-DNA among hepatitis B surface-Ag negative, anti-hepatitis B core antibody-positive blood donors in Yazd, Iran
por: Mahtab Vaziri, et al.
Publicado: (2021)

Predictive SNPs for β0-thalassemia/HbE disease severity
por: Thongperm Munkongdee, et al.
Publicado: (2021)

Chronic glucocorticoid treatment induces hepatic lipid accumulation and hyperinsulinaemia in part through actions on AgRP neurons
por: Erika Harno, et al.
Publicado: (2021)

RNAi Crop Protection Advances
por: Alejandro Hernández-Soto, et al.
Publicado: (2021)

Bayesian analysis of cytokines and chemokine identifies immune pathways of HBsAg loss during chronic hepatitis B treatment
por: Sriram Narayanan, et al.
Publicado: (2021)

Progress on RNAi-based molecular medicines
por: Chen J, et al.
Publicado: (2012)

Microparticles from β-thalassaemia/HbE patients induce endothelial cell dysfunction
por: Wasinee Kheansaard, et al.
Publicado: (2018)

High hepatitis B surface antigen levels predict insignificant fibrosis in hepatitis B e antigen positive chronic hepatitis B.
por: Wai-Kay Seto, et al.
Publicado: (2012)

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agents
por: Kamal SM
Publicado: (2014)

EXPRESSION PATTERNS OF CHEMOKINE RECEPTORS CXCR3 AND CCR6, AND THEIR LIGANDS IN PERIPHERAL BLOOD OF PATIENTS WITH CHRONIC HEPATITIS C DURING ANTIVIRAL THERAPY USING PEGYLATED INTERFERONS
por: V. V. Basina, et al.
Publicado: (2019)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
por: Arif Qayyum Khan, et al.
Publicado: (2020)

Evaluation of MicroRNA-122 as a Biomarker for Chronic Hepatitis C Infection and as a Predictor for Treatment Response to Direct-Acting Antivirals
por: Elabd NS, et al.
Publicado: (2021)